Sheeba Cantanelli, MPAS, PA-C, on HR-Positive Advanced Breast Cancer: New Findings on Entinostat and Exemestane

Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Simmons Cancer Center, discusses phase III results of a study which showed that when entinostat, an orally bioavailable HDAC inhibitor, is combined with exemestane, it can improve progression-free survival compared with exemestane alone in patients with advanced hormone receptor–positive, HER2- negative breast cancer that progressed after previous endocrine therapy. This regimen may benefit these patients with an unmet medical need (Abstract GS1-06).